Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • An HIV-Gag-SLYNTVATL-specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for 20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment (upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are given in hh[ratio]mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the upper right panel.

    PLoS Pathog 2014 10(8), e1004287. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

    PLZF-RARa–nonexpressing and -expressing PLZFRARβ3 cells were treated with 5 nmol/L romidepsin for the indicated time points. Induction of the DNA DSB marker γH2AX was measured by Western blotting. β-Actin was used as a loading control.

    Mol Cancer Ther 2013 12(8), 1591-604. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

  • Effects of combination of bort/romidepsin on HDAC6 inhibition and activation of ER stress signaling. HA cells were treated with combination of 15 nM bortezomib and 5 nM romidepsin or either drug alone for 24 hr. Expression of CHOP/GADD153 (green signals) and cleaved PARP (red signals) was detected by immunofluorescent staining. DAPI (blue signals) stained the cell nuclei.

    Int J Cancer 2014 135(12):2950-61. Romidepsin (FK228, Depsipeptide) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NXn1doRNS2WubDDWbYFjcWyrdImgRZN{[Xl? MYeyMlUuOTVibl2= NFflS5A4OiCq NESwTIdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi NYXoN2FFOjV5OUC5NFc>
U2932  M3zDd2NmdGxiVnnhZoltcXS7IFHzd4F6 NUTnOph{Oi53LUG1JI5O NYPoT4hJPzJiaB?= M3\zdYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? NIS1XoMzPTd7MEmwOy=>
OCI-LY7 NXP1[ZhsS2WubDDWbYFjcWyrdImgRZN{[Xl? NWrrV2U1Oi53LUG1JI5O NWDweVVEPzJiaB?= M4PqdYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M4iyOlI2PzlyOUC3
Farage NUPIUXR7S2WubDDWbYFjcWyrdImgRZN{[Xl? M{ixTlIvPS1zNTDuUS=> M4foe|czKGh? MorubY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? NEjueVYzPTd7MEmwOy=>
LY7/EBV MnnwR4VtdCCYaXHibYxqfHliQYPzZZk> MkmwNk42NTF3IH7N NUXWXoVXPzJiaB?= MkTPbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXSyOVc6ODlyNx?=
U2932/EBV MnjhR4VtdCCYaXHibYxqfHliQYPzZZk> M1nWVlIvPS1zNTDuUS=> MUC3NkBp MmXVbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MXuyOVc6ODlyNx?=
HCT116 NHnSdYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HPZVUuPTByMDDuUS=> MY[yOEBp NIO0VXRFVVOR MVLpcoR2[2W|IHPlcIwh\GWjdHigbY4h[SClb37j[Y51emG2aX;uMYRmeGWwZHXueEBu[W6wZYK= MVSyOVQ6OjVzNR?=
ACH-2 MVfGeY5kfGmxbjDBd5NigQ>? M3fRO|EuQSCwTR?= NGPsbpozPCCq M1rxWolv\HWlZYOgTGlXNTFiRX72JIV5eHKnc4Ppc44> MVKyOVE1QTR4Nx?=
MCF-10A MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTBwMUhCtVAvODFibl2= MkLhNlQ6PTR6NU[=
MCF-7 MoXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTFwMUFCtVAvOjBibl2= NUfVRVhUOjR7NUS4OVY>
SK-BR-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:zSFg1UUN3ME2xMlAxyrFyLkO1JI5O MojmNlQ6PTR6NU[=
MDA-MB-231 MnnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNklCtVAvOTRibl2= MlL0NlQ6PTR6NU[=
PC3 NU\FcppHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTKTWM2OD1zLk[1xtExNjN3IH7N Mkf1NlQ6PTR6NU[=
HCT116 NVHo[|BXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS2TWM2OD1zLkCwxtExNjByIH7N NIfrZo4zPDl3NEi1Oi=>
HCT116-p21-/- NVXtZWtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn3OTWM2OD1zLkK2xtExNjN5IH7N M4nqWFI1QTV2OEW2
S1 NXTDVmQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmO2TWM2OD15Lk[3xtExNjJ7IH7N MUCyOFk2PDh3Nh?=
SW620 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnTe|N6UUN3ME2wMlk{yrFyLkK5JI5O M13DNlI1QTV2OEW2
LOX-IMVI M1;DSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LafWlEPTB;MD64O:KyOC5yMzDuUS=> NF7LRmkzPDl3NEi1Oi=>
UACC-62 NIfDW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjZVYpKSzVyPUCuOVbDuTBwMU[gcm0> NYP1dnJFOjR7NUS4OVY>
MDA-MB-435 NF75OVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zPd2lEPTB;MD65NOKyOC5yNjDuUS=> M3mwbVI1QTV2OEW2
SF-295 M1yxdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwOElCtVAvOTVibl2= M1:4c|I1QTV2OEW2
A549 NUT6PGJHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moi2TWM2OD1zLkK2xtExNjJ2IH7N MXKyOFk2PDh3Nh?=
H460 M4WzfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ZV2lEPTB;Mj61POKyOC56MDDuUS=> MViyOFk2PDh3Nh?=
EKVX MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDHT|FrUUN3ME2xMlM{yrFyLkO0JI5O MoDDNlQ6PTR6NU[=
H146 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTBwMkNCtVAvODdibl2= NGLqU20zPDl3NEi1Oi=>
H526 NGDyfnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH0TWM2OD1yLkG1xtExNjB|IH7N NX\GPWhLOjR7NUS4OVY>
HuT-78 MkLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1y3[WlEPTB;MT63N:KyOC52NDDuUS=> MXmyOFk2PDh3Nh?=
HA NVLEfmQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nd3oxNjZ{NT2xNI5O NWrFNmlzPDhiaB?= MmTQbY5lfWOnczDhJJNq\26rZnnjZY51dHlic4Tyc45o\XJiaX7obYJqfGmxbjDv[kBk\WyuIIDyc4xq\mW{YYTpc44h[29vdILlZZRm\CC5aYToJIJwenSnen;tbYI> Mlm2NlQ4PzF3MUC=
MS-275 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYewMlYzPS1zMH7N MnLROFghcA>? NG\vRVBqdmS3Y3XzJIEhe2mpbnnmbYNidnSueTDzeJJwdmencjDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdiClbz30doVifGWmIIfpeIgh[m:{dHX6c41q[g>? M2G4elI1PzdzNUGw
CD4 T MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm0PEBp NVTTWYxPTUN3ME20MlXDuTFwMDDuUS=> MWmyOFczOjR3NB?=
CD4 T NEnnRZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYS0PEBp M3fTUmNEPTB;MUC3xtEyOjZibl2= M3q2cVI1PzJ{NEW0
CD4+ T MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLMRm5GSzVyPUOgcm0> NXKyZpFDOjR2OUWxNFU>
A549 M3XwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLTNVDjiJNzMEFCpI5O NVT1SW1jOjRxM{[vOFghcA>? NYDUXmY1cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCClb37j[Y51emG2aX;uMUBidmRidHnt[U1l\XCnbnTlcpQhdWGwbnXy MmHnNlQ1QDV5OUm=
JJN3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfjNlQwPDhiaB?= NXnyT2JlTUN3MEyx5qCKdk19IES45qCKcA>? MlTRNlQxOzBzNUC=
OPM-2 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV[yOE81QCCq M1X5eGVEPTC|PUJihKlvVTtiNElihKlp MoTONlQxOzBzNUC=
RPMI-8226 NXHDO4EyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTyRWsxOjRxNEigbC=> NHS2UYlGSzVyc{2xMljjiImwTUugOFjjiImq Mn;JNlQxOzBzNUC=
U266 M33vXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jPOVI1NzR6IHi= MV\FR|Uxez1zMPMAjY5OQyB2OPMAjYg> MXOyOFA{ODF3MB?=
CA46 MnPPRZBweHSxc3nzJGF{e2G7 NXjSRmM{PiCq MVfpcoR2[2W|IHLseY51KGGyb4D0c5Nqew>? MUmyN|k3PjF4NB?=
DG75 NIDQ[XhCeG:ydH;zbZMhSXO|YYm= NUfncHA2PiCq Mn3HbY5lfWOnczDuc{BieG:ydH;zbZM> NHfueZozOzl4NkG2OC=>
Ramos NHP1T5hCeG:ydH;zbZMhSXO|YYm= NX63W3d{PiCq M1S3UYlv\HWlZYOg[Zh1\W6|aY\lJIFxd3C2b4Ppdy=> MVyyN|k3PjF4NB?=
ST486 MkDtRZBweHSxc3nzJGF{e2G7 M1n1cVYhcA>? NWm3dYZEcW6mdXPld{BmgHSnboPpeoUh[XCxcITvd4l{ NGLoUVYzOzl4NkG2OC=>
HuT78 NIHH[4VCeG:ydH;zbZMhSXO|YYm= NVzlVnFYOS9zMD:xNFAhdk1? M3vWbFQ5KGh? M3u1OYlv\HWlZYOgZZBweHSxc3nzJIF1KDFibl2= NH:ydZkzOzV|MkezNi=>
DpVp35 M3HnXmFxd3C2b4Ppd{BCe3OjeR?= MlPDNU8yOC9zMECgcm0> MorjOFghcA>? MmDLbY5lfWOnczDicJVvfCCjcH;weI9{cXN? MlT3NlM2OzJ5M{K=
DpVp50 MUXBdI9xfG:|aYOgRZN{[Xl? MVOxM|ExNzFyMDDuUS=> MlHqOFghcA>? NUHuXmE6cW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= MWmyN|U{Ojd|Mh?=
DpP75  MUnBdI9xfG:|aYOgRZN{[Xl? M4HUZlEwOTBxMUCwJI5O MUG0PEBp M1vmV4lv\HWlZYOgZox2dnRiYYDvdJRwe2m| MUGyN|U{Ojd|Mh?=
SKOV-3 NYHLTYdCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX2x5qCUOjCwTR?= M4qyb|czKGh? NWfG[Io2TE2VTx?= M1qwXJJm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv NYP2O2JoOjNyMUCzOFg>
Brca1 WT MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS3SlUy6oDVMkDuUS=> NY[1VplkPzJiaB?= MW\EUXNQ NFPCVZpz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>? NEfG[nEzOzBzMEO0PC=>
Brca1 Null M{jrcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr6VYNFOeLCk{Kwcm0> MV23NkBp NXLVSYdITE2VTx?= MlridoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> MnO3NlMxOTB|NEi=
OVCAR-8  NIfz[VBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfiWoYy6oDVMkDuUS=> MYe3NkBp NF2yXpZFVVOR M2q5W5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MVOyN|AyODN2OB?=
NCI/ADR-RES NVjKbXg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDQOmp6OeLCk{Kwcm0> M4XuNVczKGh? NYnyWHB{TE2VTx?= NWfhcW9LemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MX2yN|AyODN2OB?=
HCT116 NYXieWRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnhOUBvVS13MDFOwG0> NH3sb|MzPCCq MX3EUXNQ M{O2colvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz MVGyNlkzPDl3OB?=
RKO MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nHUlUhdk1vNUCg{txO MmHGNlQhcA>? NWPOc|FSTE2VTx?= MWjpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> NXiydFVKOjJ7MkS5OVg>
CO115 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1GydFUhdk1vNUCg{txO MmGyNlQhcA>? NHv2WJRFVVOR NEDxUmFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NXvKZoxIOjJ7MkS5OVg>
HFS MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PTVFUhdk1? MkfONlQwPDhxN{KgbC=> M{TFWolvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk> NIrRZ24zOjFyNkK4Ni=>
LNCaP Mn:zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fHNFUhdk1? NEPWdXIzPC92OD:3NkBp NWf3bXpXcW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>? M4js[lIzOTB4Mkiy
A549 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHzdm9QPSCwTR?= MWKyOE81QC95MjDo Mke0bY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZT3k[ZBmdmSnboTsfS=> MmHNNlIyODZ{OEK=
697  M4f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\S[I9KSzVy4pEJQgKBkTJwNdMgcm0> M2nX[VIyPTN6MkG2
697-R NVvwVXl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFG0enFKSzVy4pEJQgKBkThwNtMgcm3DqA>? M4DZTlIyPTN6MkG2
HUT78 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF7PR5lKSzVyPUGgcm0> MU[yNVE6QDV2NR?=
THJ-16T MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyxJI5O MVSyOEBp NIrFPYlqdmirYnn0d{Bk\WyuIHfyc5d1cA>? MV[yNFgyODV4OB?=
HCT116 MXTGeY5kfGmxbjDBd5NigQ>? NWDHT5VrOjBibl2= NGXzOmU5KGh? NH7jNYlud2S3bHH0[ZMhfHKjboPjdolxfCCuZY\lcJMh\m:{IHj1coRz\WS|IH;mJIdmdmW|IHnuJIVqfGincjDkbZJm[3Srb36= NF7tdIczODd|OUS1OC=>
B104  M3WyXmZ2dmO2aX;uJGF{e2G7 NWrWOJhlOiCwTR?= M3nSSlI1NzR6L{eyJIg> MYPpcoNz\WG|ZYOgeIhmKHO3cn\hZ4Uh\XiycnXzd4lwdiCxZjDDSFIxyqB? NI\6WmwzODZ6NkWwOS=>
HL-60  Mm\aR5l1d3SxeHnjbZR6KEG|c3H5 NGH4VWsyNTVyMDDuUS=> MV:yOEBp MVrpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NUmzR5Z2OjB4MkSxOlM>
HP100 MojMR5l1d3SxeHnjbZR6KEG|c3H5 NUnnUXZFOS13MECgcm0> NHPKN4czPCCq MWLpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh Mo\ONlA3OjRzNkO=
HL-60  M4Xkb2Z2dmO2aX;uJGF{e2G7 NHXOeGEyOCCwTR?= Mlv2OE83NzF4IHi= NVy0bWxKcW6mdXPld{B1cGViZ3Xu[ZJifGmxbjDv[kBpgWS{b3flckBx\XKxeHnk[UBnem:vIETo Mne0NlA3OjRzNkO=
HP100 MnHoSpVv[3Srb36gRZN{[Xl? M3vBSlExKG6P NV\QNIJ6PC94L{G2JIg> MWjpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh? NUjPfHkzOjB4MkSxOlM>
HL-60  NU\4N4ZuTnWwY4Tpc44hSXO|YYm= NW\6TmhMOTBvNUCwJI5O Mm\pOEBp M4fkXoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= M37WO|IxPjJ2MU[z
HP100 MV;GeY5kfGmxbjDBd5NigQ>? MmLmNVAuPTByIH7N NUiwVFh2PCCq NECzeVZl\WO{ZXHz[ZMhfGinIHjpd5RwdmViZHXhZ4V1gWyjc3WgLGhFSUNrIHHjeIl3cXS7wrC= M4rUeFIxPjJ2MU[z
11z NIi4WGdMcW6jc3WgRZN{[Xl? M2TkPVMuOTByIH7N NELne3Jz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NYXh[ZIxOjB4MEWxOFQ>
SKOV-3 MkXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX60M|gwOTZibl2= MVe0PEBp NUnXbo4{cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NIHEV28zODRyNEW2OC=>
OVCAR-3 NXLFNm9OT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnaOE85NzF4IH7N M1\SN|Q5KGh? NHjGXINqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MlnpNlA1ODR3NkS=
HBL-2 NVy3dY1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;GNk0yOCCwTR?= NWqwUpprOjRiaB?= M{O0RmlEPTB;ND6zJI5O MnLVNlAxPjhyOEC=
Jeko-1 NUHu[nlmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV73UHh3Oi13MDDuUS=> NXLjVIZiOjRiaB?= NXX0UFVZUUN3ME2xNUBvVQ>? MkTxNlAxPjhyOEC=
Granta-519 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfUcFY2PS12MDDuUS=> M3XLb|I1KGh? NHz3bJJKSzVyPUW4MlUhdk1? NID0S|EzODB4OEC4NC=>
L1236 Ml\wR5l1d3SxeHnjbZR6KEG|c3H5 MlP4NUBvVS1zMECg{txO NUXOS2pnPDhiaB?= M1XtTGVEPTB;MD6wO{DPxE1? M3HXblE6OjN|NEew
L428 MVLDfZRwfG:6aXPpeJkhSXO|YYm= MlH6NUBvVS1zMECg{txO NGXRe2U1QCCq NGfl[HJGSzVyPUCuOFMh|ryP NU\iPHZZOTl{M{O0O|A>
KM-H2 NELaVY5EgXSxdH;4bYNqfHliQYPzZZk> M{PIVFEhdk1vMUCwJO69VQ>? NXn3ZWtxPDhiaB?= NVWxc5o1TUN3ME2wMlU5KM7:TR?= NXv5cGJzOTl{M{O0O|A>
L540Cy M2fXO2N6fG:2b4jpZ4l1gSCDc4PhfS=> Mn\nNUBvVS1zMECg{txO NGDOPFg1QCCq NIW4ZXBGSzVyPUCuNVYh|ryP NXHqflNOOTl{M{O0O|A>
G401 MkPXSpVv[3Srb36gRZN{[Xl? NWrRXFU3OTBibl2= Ml62NlQwPDhxN{KgbC=> MoH5SG1UVw>? NIjnUWtqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MWOxPVIzOTV6Nh?=
STM91-01 MoD4SpVv[3Srb36gRZN{[Xl? NX35cVBvOTBibl2= M33CR|I1NzR6L{eyJIg> MYXEUXNQ MWHpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= Mle5NVkzOjF3OE[=
SJSC  NInHenJHfW6ldHnvckBCe3OjeR?= M1rleVExKG6P NVjPNZFbOjRxNEivO|IhcA>? MXXEUXNQ MUjpcoNz\WG|ZYOgR2RMVjGFIHX4dJJme3Orb36= Mm\iNVkzOjF3OE[=
BT16  M3SxfGZ2dmO2aX;uJGF{e2G7 NWLD[XZ6OTBibl2= M4ixSlI1NzR6L{eyJIg> MVPEUXNQ NYW2e2pScW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MXuxPVIzOTV6Nh?=
NCI-H1299 M3\kc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXkSmZKUUN3ME20MlbDuTBwMjDu[{9udA>? MnrlNVkyPzl6OUC=
NCI-2882 NEXrOmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG0R2xoUUN3ME2xMlbDuTBwMESgcocwdWx? MorTNVkyPzl6OUC=
HCC95 NV65fY5oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3HfZpKSzVyPUKuOeKyOC5yNTDu[{9udA>? NVn3PIVyOTlzN{m4PVA>
NCI-H23 MofDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[xTWM2OD1{LkpCtVAvOiCwZz;tcC=> MVKxPVE4QTh7MB?=
NCI-H157 M1TQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\aTWM2OD1zLkdCtVAvODJibnevcYw> Mn[wNVkyPzl6OUC=
NCI-H460 NVTSTYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTJwMdMxNE4xPyCwZz;tcC=> MlnSNVkyPzl6OUC=
NCI-H1975 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NED5ZlRKSzVyPUGuN:KyOC5yNDDu[{9udA>? M4nQ[FE6OTd7OEmw
NCI-H820 NVT6NHRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEi1O4hKSzVyPUKuOOKyOC5zIH7nM41t NWLCWGwzOTlzN{m4PVA>
NCI-H1650 NHrqTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI\TbmdKSzVyPUSuPeKyOC5|IH7nM41t NH;sNFgyQTF5OUi5NC=>
DTC1 MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnjCTWM2OD1yLkWxJI5O NYDSNpNoOTh3Nk[yOFY>
KAO M4fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H2[GlEPTB;MD65NUBvVQ>? NF7i[YUyQDV4NkK0Oi=>
SU-CCS-1 M1[4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYDZRYpbUUN3ME2wMlg6KG6P NXq3RppuOTh3Nk[yOFY>
SYO-1 NI\M[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHrTWM2OD1yLk[3JI5O Mo\nNVg2PjZ{NE[=
FUJI NVHOPJVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLvd|BLUUN3ME2xMlMyKG6P MkexNVg2PjZ{NE[=
SKNMC NGPXVoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzQTWM2OD1zLkG3JI5O MXixPFU3PjJ2Nh?=
402-91 NYnCNGl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMk[gcm0> MoLjNVg2PjZ{NE[=
1765-92 MoD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXvU2xKSzVyPUGuO|chdk1? NV3LcmtnOTh3Nk[yOFY>
JN-DSRCT-1 NWDuSIVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmGwTWM2OD1zLkK1JI5O MX6xPFU3PjJ2Nh?=
NMS-2PC M2DjRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfvO|hKSzVyPUCuPFEhdk1? NXfTUYRZOTh3Nk[yOFY>
HL60 NILFe3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2z[49KSzVyPUGuPFYhdk1? M1zlTlE5PTZ4MkS2
A549 NXHqZohYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4r2T2lEPTB;Mz6yOEBvVQ>? Mn34NVg2PjZ{NE[=
SW480 NXPZWJdZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPubJRkUUN3ME2yMlY6KG6P NVnVNHpQOTh3Nk[yOFY>
MCF7 NF23RlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjROY9KSzVyPUOuOVUhdk1? M4TYOVE5PTZ4MkS2
PC-3 NH7CR|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXaTWM2OD1{LkWxJI5O NXz2XlNIOTh3Nk[yOFY>
MMRU M3rBSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXrSpY{UUN3ME2yMlU4KG6P NWrDcnZPOTh3Nk[yOFY>
Hs68 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;kTGRVUUN3ME2+NVAhdk1? NWHQdFY3OTh3Nk[yOFY>
hMSC-001F M1jMZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGn3[2pKSzVyPU6xNEBvVQ>? NG\EOWoyQDV4NkK0Oi=>

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]

+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]

+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water slightly soluble or insoluble
Ethanol slightly soluble or insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage powder
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00048334 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 26, 2002 Phase 1
NCT00094978 Terminated Carcinoma, Small Cell|Carcinoma, Non-Small-Cell Lung|Esophageal Neoplasms|Mesothelioma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) October 25, 2004 Phase 1
NCT01445340 Terminated Mycosis Fungoides|Cutaneous T-Cell Lymphoma|Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) April 21, 2007 Phase 1
NCT02616965 Not yet recruiting Cutaneous T-cell Lymphoma (CTCL) Fox Chase Cancer Center|Seattle Genetics, Inc.|Celgene Corporation April 2017 Phase 1
NCT02850016 Recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aarhus University Hospital December 2016 Phase 2
NCT02757248 Withdrawn PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University November 2016 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID